Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations

Vaccine

Volumn 33, Issue 26, 2015, Pages 3016-3025

  Kreiss, A ^a   Brown, G K ^a,c   Tovar, C ^a   Lyons, A B ^b   Woods, G M ^a,b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c NONE   (Australia)

Author keywords

Devil facial tumor disease (DFTD); ELISA; Flow cytometry; Marsupial; Montanide; Tasmanian devil; Transmissible cancer; Veterinary immunology

Indexed keywords

CANCER VACCINE; CPG 1585; CPG 1668; CPG OLIGODEOXYNUCLEOTIDE; DEVIL FACIAL TUMOR DISEASE VACCINE; MONTANIDE ISA 51; UNCLASSIFIED DRUG; CANCER ANTIBODY; IMMUNOLOGICAL ADJUVANT; MANNITOL; OLEIC ACID;

ADJUVANT THERAPY; ADULT; ANIMAL CELL; ANIMAL VENEREAL TUMOR; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; DEVIL FACIAL TUMOR DISEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDANGERED SPECIES; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALE; NEURILEMOMA; NONHUMAN; PRIORITY JOURNAL; SARCOPHILUS HARRISII; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; ANIMAL; AUSTRALIA; BLOOD; CELL LINE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIAL NEOPLASMS; HUMAN; IMMUNOLOGY; MARSUPIAL; VACCINATION; VETERINARY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; AUSTRALIA; CANCER VACCINES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACIAL NEOPLASMS; HUMANS; IMMUNITY, HUMORAL; MANNITOL; MARSUPIALIA; OLEIC ACIDS; VACCINATION;

EID: 84930541205     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.039     Document Type: Article

References (39)

1. Pearse A.M., Swift K. Allograft theory: transmission of devil facial-tumour disease. Nature 2006, 439:549.
2. Hawkins C.E., Baars C., Hesterman H., Hocking G.J., Jones M.E., Lazenby B., et al. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol Conserv 2006, 131:307-324.
3. Murchison E.P., Schulz-Trieglaff O.B., Ning Z., Alexandrov L.B., Bauer M.J., Fu B., et al. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 2012, 148:780-791.
4. McCallum H., Tompkins D.M., Jones M., Lachish S., Marvanek S., Lazenby B., et al. Distribution and impacts of Tasmanian devil facial tumour disease. Ecohealth 2007, 4:318-325.
5. Murchison E.P., Tovar C., Hsu A., Bender H.S., Kheradpour P., Rebbeck C.A., et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010, 327:84-87.
6. Siddle H.V., Kreiss A., Eldridge M.D., Noonan E., Clarke C.J., Pyecroft S., et al. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci U S A 2007, 104:16221-16226.
7. Siddle H.V., Kreiss A., Tovar C., Yuen C.K., Cheng Y.Y., Belov K., et al. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci U S A 2013, 110:5103-5108.
8. Loh R., Bergfeld J., Hayes D., O'Hara A., Pyecroft S., Raidal S., et al. The pathology of devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet Pathol 2006, 43:890-895.
9. Kreiss A., Fox N., Bergfeld J., Quinn S.J., Pyecroft S., Woods G.M., et al. Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol 2008, 32:544-553.
10. Hamede R., Lachish S., Belov K., Woods G., Kreiss A. Reduced effect of Tasmanian devil facial tumor disease at the disease front. Conserv Biol 2011, 26:124-134.
11. Pyecroft S.B., Pearse A.M., Loh R., Swift K., Belov K., et al. Towards a case definition for devil facial tumour disease: what is it?. Ecohealth 2007, 4:346-351.
12. Kreiss A., Obendorf D.L., Hemsley S., Canfield P.J., Woods G.M. A histological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil. Anat Rec (Hoboken) 2009, 292:611-620.
13. Kreiss A., Wells B., Woods G.M. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet Immunol Immunopathol 2009, 130:135-137.
14. Kreiss A., Cheng Y., Kimble F., Wells B., Donovan S., Belov K., et al. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS ONE 2011, 6:e22402.
15. Brown G.K., Kreiss A., Lyons A.B., Woods G.M. Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS ONE 2011, 6:e24475.
16. Pinfold T.L., Brown G.K., Bettiol S.S., Woods G.M. Mouse model of devil facial tumour disease establishes that an effective immune response can be generated against the cancer cells. Front Immunol 2014, 5:251.
17. Jang S.I., Lillehoj H.S., Lee S.H., Lee K.W., Lillehoj E.P., Bertrand F., et al. Montanide ISA 71 VG adjuvant enhances antibody and cell-mediated immune responses to profilin subunit antigen vaccination and promotes protection against Eimeria acervulina and Eimeria tenella. Exp Parasitol 2011, 127:178-183.
18. Langermans J.A., Hensmann M., van Gijlswiik M., Zhang D., Pan W., Giersing B.K., et al. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Hum Vaccin 2006, 2:222-226.
19. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997, 15:176-178.
20. Quattrocchi V., Pappalardo J.S., Langellotti C., Smitsaart E., Fondevila N., Zomorano P., et al. Early protection against foot-and-mouth disease virus in cattle using an inactivated vaccine formulated with Montanide ESSAI IMS D 12802 VG PR adjuvant. Vaccine 2014, 32:2167-2172.
21. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8T cells through cross-priming. Proc Natl Acad Sci U S A 2007, 104:8947-8952.
22. Eastcott J.W., Holmberg C.J., Dewhirst F.E., Esch T.R., Smith D.J., Taubman M.A., et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 2001, 19:1636-1642.
23. Linghua Z., Xingshan T., Fengzhen Z. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets. Vaccine 2008, 26:224-233.
24. Mapletoft J.W., Oumouna M., Townsend H.G., Gomis S., Babiuk L.A., van Drunen Littel-van den Hurk S., et al. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 2006, 353:316-323.
25. Mendez S., Tabbara K., Belkaid Y., Bertholet S., Verthelyi D., Klinman D., et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun 2003, 71:5121-5129.
26. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188:2335-2342.
27. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746.
28. Pearse A.M., Swift K., Hodson P., Hua B., McCallum H., Pyecroft S., et al. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population. Cancer Genet 2012, 205:101-112.
29. Howson L.J., Morris K.M., Kobayashi T., Tovar C., Kreiss A., Papenfuss A.T., et al. Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors. Anat Rec (Hoboken) 2014, 297:925-938.
30. Woods G.M., Kreiss A., Belov K., Siddle H.V., Obendorf D.L., Muller H.K., et al. The immune response of the Tasmanian Devil (Sarcophilus harrisii) and devil facial tumour disease. Ecohealth 2007, 4:338-345.
31. Chiang C.L., Benencia F., Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010, 22:132-143.
32. Miller W., Hayes V.M., Ratan A., Petersen D.C., Wittekindt N.E., Miller J., et al. Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci U S A 2011, 108:12348-12353.
33. Higgins D., Marshall J.D., Traquina P., Van Nest G., Livingston B.D. Immunostimulatory DNA as a vaccine adjuvant. Exp Rev Vaccines 2007, 6:747-759.
34. Wilkinson R., Kotlarski I., Barton M. Koala lymphoid cells: analysis of antigen-specific responses. Vet Immunol Immunopathol 1992, 33:237-247.
35. Wilkinson R., Kotlarski I., Barton M. Further characterisation of the immune response of the koala. Vet Immunol Immunopathol 1994, 40:325-339.
36. Binder R.J. Functions of heat shock proteins in pathways of the innate and adaptive immune system. J Immunol 2014, 193:5765-5771.
37. Santin A.D., Rose G.S., Hiserodt J.C., Fruehauf J., Eck L.M., Garcia R.I., et al. Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer 1996, 65:688-694.
38. Guiler E.R. Sarcophilus harrisii (Marsupialia: Dasyuridae) II. Reproduction, breeding, and growth of pouch young. Aust J Zool 1970, 18:63-70.
39. Hamede R., McCallum H., Jones M.E. Seasonal, demographic and density-related patterns of contact between Tasmanian devils (Sarcophilus harrisii): implications for transmission of devil facial tumour disease. Austral Ecol. 2008, 33:614-622.